Pharmacologic reversal of serious or intolerable side effects (SISE) from vasodilator stress is an important safety and comfort measure for patients experiencing such effects. While typically performed using intravenous aminophylline, recurrent shortages of this agent have led to a greater need to limit its use and consider alternative agents. This information statement provides background and recommendations addressing indications for vasodilator reversal, timing of a reversal agent, incidence of observed SISE with vasodilator stress, clinical and logistical considerations for aminophylline-based reversal, and alternative non-aminophylline based reversal protocols.

中文翻译：

---

氨茶碱的短缺和目前逆转血管舒张压的建议：SCMR批准的ASNC信息声明。

舒张血管舒张压引起的严重或无法忍受的副作用（SISE）的药理学逆转是一种重要的安全性和舒适性措施，适用于经历这种作用的患者。尽管通常使用静脉给予氨茶碱进行治疗，但这种药物的反复短缺导致人们更加需要限制其使用并考虑使用其他药物。本信息声明提供背景和建议，涉及血管扩张剂逆转的适应症，逆转药物的时机，观察到的具有血管扩张剂应激的SISE发生率，基于氨茶碱的逆转的临床和后勤考虑以及基于非氨茶碱的逆转方案的替代方案。